CStone Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
CStone Pharmaceuticals has a total shareholder equity of CN¥467.7M and total debt of CN¥306.4M, which brings its debt-to-equity ratio to 65.5%. Its total assets and total liabilities are CN¥1.5B and CN¥1.1B respectively.
Key information
65.5%
Debt to equity ratio
CN¥306.42m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥857.65m |
| Equity | CN¥467.66m |
| Total liabilities | CN¥1.06b |
| Total assets | CN¥1.53b |
Recent financial health updates
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Recent updates
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise
Oct 04Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified
May 12Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Financial Position Analysis
Short Term Liabilities: 2616's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥713.2M).
Long Term Liabilities: 2616's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥351.2M).
Debt to Equity History and Analysis
Debt Level: 2616 has more cash than its total debt.
Reducing Debt: 2616's debt to equity ratio has increased from 0% to 65.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2616 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 2616 has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 8.1% each year.